Combo Therapy vs Insulin: Type 2 Diabetes

Video

The Qatar Study investigated the efficacy of exenatide plus pioglitazone versus basal-bolus insulin in poorly-controlled type 2 diabetes.

The Qatar Study investigated the efficacy of combination therapy with exenatide plus pioglitazone versus basal-bolus insulin.

The study, published in Diabetes Care, randomized 231 patients with poorly controlled type 2 diabetes on a sulfonylurea and metformin to receive either exenatide plus pioglitazone or insulin therapy.

After a mean follow up of 12 months, combination therapy caused a significantly greater decrease in HbA1c vs insulin therapy, dropping from a mean HbA1c of 10 to 6.1%.

In addition, patients in the insulin group had a significantly greater weight gain and more episodes of hypoglycemia.

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
© 2024 MJH Life Sciences

All rights reserved.